Physician profile
Robert A Ecker
NPI 1194701284
$1,396.69
in general payments reported to CMS, 2019-2025
23 companies · $42.41 in 2025
The $42.41 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,295 · 2020: $17.39 · 2022: $20.76 · 2024: $21.05 · 2025: $42.41.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $63.46.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $63.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $195.07 | 2019 | |
| Astrazeneca Pharmaceuticals Lp | $153.61 | 2019 | |
| Glaxosmithkline, LLC. | $143.22 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $123.12 | 2019 | |
| Janssen Pharmaceuticals, INC | $108.90 | 2019 | |
| Amgen INC. | $99.92 | 2019 | |
| Amarin Pharma, INC. | $70.79 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $65.85 | 2019 | |
| Astellas Pharma US INC | $61.93 | 2019 | |
| Lilly USA, LLC | $51.25 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $44.66 | 2019 | |
| Imperative Care, INC | $42.41 | 2025 | Zoom Reperfusion Catheter |
| Takeda Pharmaceuticals U.S.A., INC. | $35.13 | 2019 | |
| Genentech USA, INC. | $29.88 | 2019 | |
| Novartis Pharmaceuticals Corporation | $27.83 | 2019 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Antares Pharma, INC. | $23.65 | 2019 | |
| Sanofi-Aventis U.S. LLC | $23.10 | 2019 | |
| Abbvie INC. | $21.05 | 2024 | |
| Alkermes, INC. | $20.76 | 2022 | |
| Mission Pharmacal Company | $17.33 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $13.10 | 2019 | |
| Pfizer INC. | $12.33 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $11.80 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Ecker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.